Clearside Biomedical Analyst Ratings
Clearside Biomedical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 11/06/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/15/2023 | 395.05% | JMP Securities | → $5 | Reiterates | Market Outperform → Market Outperform |
| 08/15/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/15/2023 | 296.04% | Needham | → $4 | Reiterates | Buy → Buy |
| 07/19/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/12/2023 | 395.05% | JMP Securities | → $5 | Reiterates | Market Outperform → Market Outperform |
| 07/10/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 06/14/2023 | 494.06% | JonesTrading | → $6 | Initiates Coverage On | → Buy |
| 06/01/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 05/12/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 04/28/2023 | 494.06% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 04/20/2023 | 296.04% | Needham | → $4 | Reiterates | → Buy |
| 04/19/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/10/2023 | 494.06% | JMP Securities | $7 → $6 | Maintains | Market Outperform |
| 03/10/2023 | 494.06% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/10/2023 | 296.04% | Needham | $5 → $4 | Maintains | Buy |
| 02/13/2023 | 593.07% | JMP Securities | → $7 | Reiterates | → Market Outperform |
| 02/03/2023 | 395.05% | Needham | → $5 | Reiterates | → Buy |
| 11/10/2022 | 692.08% | Stifel | → $8 | Upgrades | Hold → Buy |
| 11/10/2022 | 395.05% | Needham | → $5 | Upgrades | Hold → Buy |
| 11/10/2022 | 494.06% | HC Wainwright & Co. | $5 → $6 | Maintains | Buy |
| 08/10/2022 | 395.05% | HC Wainwright & Co. | $10 → $5 | Maintains | Buy |
| 03/11/2022 | 890.1% | JMP Securities | $11 → $10 | Maintains | Market Outperform |
| 07/29/2021 | 890.1% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 06/17/2021 | 1682.18% | Wedbush | $6 → $18 | Maintains | Outperform |
| 06/15/2021 | 791.09% | JMP Securities | $8 → $9 | Maintains | Market Outperform |
| 05/13/2020 | 692.08% | Roth Capital | → $8 | Initiates Coverage On | → Buy |
| 01/27/2020 | 395.05% | Wedbush | $3 → $5 | Maintains | Outperform |
| 日期 | 上行/下行 | 分析師公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 11/06/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 08/15/2023 | 395.05% | JMP 證券 | → 5 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 08/15/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 08/15/2023 | 296.04% | 尼德姆 | → 4 美元 | 重申 | 購買 → 購買 |
| 07/19/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 07/12/2023 | 395.05% | JMP 證券 | → 5 美元 | 重申 | 市場跑贏大盤 → 市場跑贏大盤 |
| 07/10/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 06/14/2023 | 494.06% | JonesTrading | → 6 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/01/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 05/12/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | 購買 → 購買 |
| 04/28/2023 | 494.06% | JMP 證券 | → 6 美元 | 重申 | → 市場跑贏大盤 |
| 04/20/2023 | 296.04% | 尼德姆 | → 4 美元 | 重申 | → 購買 |
| 04/19/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 03/10/2023 | 494.06% | JMP 證券 | 7 美元 → 6 美元 | 維護 | 市場表現跑贏大盤 |
| 03/10/2023 | 494.06% | HC Wainwright & Co. | → 6 美元 | 重申 | → 購買 |
| 03/10/2023 | 296.04% | 尼德姆 | 5 美元 → 4 美元 | 維護 | 買 |
| 02/13/2023 | 593.07% | JMP 證券 | → 7 美元 | 重申 | → 市場跑贏大盤 |
| 02/03/2023 | 395.05% | 尼德姆 | → 5 美元 | 重申 | → 購買 |
| 2022 年 10 月 11 日 | 692.08% | Stifel | → 8 美元 | 升級 | 持有 → 買入 |
| 2022 年 10 月 11 日 | 395.05% | 尼德姆 | → 5 美元 | 升級 | 持有 → 買入 |
| 2022 年 10 月 11 日 | 494.06% | HC Wainwright & Co. | 5 美元 → 6 美元 | 維護 | 買 |
| 08/10/2022 | 395.05% | HC Wainwright & Co. | 10 美元 → 5 美元 | 維護 | 買 |
| 03/11/2022 | 890.1% | JMP 證券 | 11 美元 → 10 美元 | 維護 | 市場表現跑贏大盤 |
| 2021 年 7 月 29 日 | 890.1% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 06/17/2021 | 1682.18% | Wedbush | 6 美元 → 18 美元 | 維護 | 跑贏大盤 |
| 06/15/2021 | 791.09% | JMP 證券 | 8 美元 → 9 美元 | 維護 | 市場表現跑贏大盤 |
| 05/13/2020 | 692.08% | 羅斯資本 | → 8 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 1 月 27 日 | 395.05% | Wedbush | 3 美元 → 5 美元 | 維護 | 跑贏大盤 |
What is the target price for Clearside Biomedical (CLSD)?
Clearside Biomedical（CLSD）的目標價格是多少？
The latest price target for Clearside Biomedical (NASDAQ: CLSD) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $6.00 expecting CLSD to rise to within 12 months (a possible 494.06% upside). 19 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月14日公佈了Clearside Biomedical（納斯達克股票代碼：CLSD）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計CLSD將在12個月內升至12個月內（可能上漲494.06％）。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Clearside Biomedical (CLSD)?
Clearside Biomedical（CLSD）的最新分析師評級是多少？
The latest analyst rating for Clearside Biomedical (NASDAQ: CLSD) was provided by HC Wainwright & Co., and Clearside Biomedical reiterated their buy rating.
HC Wainwright & Co. 提供了Clearside Biomedical（納斯達克股票代碼：CLSD）的最新分析師評級，Clearside Biomedical重申了其買入評級。
When is the next analyst rating going to be posted or updated for Clearside Biomedical (CLSD)?
Clearside Biomedical（CLSD）的下一次分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clearside Biomedical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clearside Biomedical was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Clearside Biomedical的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Clearside Biomedical的最新評級是在2023年11月14日發佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Clearside Biomedical (CLSD) correct?
分析師對Clearside Biomedical（CLSD）的評級正確嗎？
While ratings are subjective and will change, the latest Clearside Biomedical (CLSD) rating was a reiterated with a price target of $0.00 to $6.00. The current price Clearside Biomedical (CLSD) is trading at is $1.01, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Clearside Biomedical（CLSD）評級得到了重申，目標股價爲0.00美元至6.00美元。Clearside Biomedical（CLSD）目前的交易價格爲1.01美元，在分析師的預測區間內。